Metabolic Syndrome and Its Associations with Surgery

• Authors: Witold Woźniak , Tomasz Miłek
• Languages of publication: EN

Abstracts

EN

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2009
• Volume: 81
• Issue: 9
• Pages: 419-429

Dates

published

1 - 9 - 2009

online

4 - 9 - 2009

Contributors

author

Witold Woźniak

• Chair and Clinic of General and Vascular Surgery, 2nd Medical Division, Warsaw Medical University

author

Tomasz Miłek

• Chair and Clinic of General and Vascular Surgery, 2nd Medical Division, Warsaw Medical University

References

• Reaven G: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.[Crossref][PubMed]
• Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-20.
• International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome.
• Erkelens DW, de Bruin TW, Castro Cabezas M: Tulp syndrome. Lancet 1993; 342: 1536-37.
• Enzi G, Busetto L, Inelmen EM: Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni's ‘De sedibus et causis morborum per anatomen indagatis’. Int J Obes Relat Metab Disord 2003; 27: 534-35.[Crossref]
• Kylin E: Studien über das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentralblatt für Innere Medizin 1923; 44:105-27.
• Węgierko J: Znaczenie praktyczne podziału cukrzycy na poszczególne jej postacie. Pol Arch Med Wewn 1955; 25: 791-97.
• Hanefeld M, Leonhardt W: Das metabolische Syndrome. Dt Gesundh-Wesen 1981; 36: 545-51.
• Tatoń J, Czech A, Bernas M: Zespół metaboliczny: zaburzenia metaboliczne i kliniczne indukowane przez insulinooporność i otyłość brzuszną. Diagnostyka, prewencja i leczenie. W: Tatoń J, Czech A, Bernas M (red) Otyłość. Zespół metaboliczny. Wyd. 1. PZWL, Warszawa 2006, s. 202-25.
• Grzeszczak W: Zespół metaboliczny - definicja, rys historyczny, epidemiologia. W: Mamcarz A (red.) Zespół metaboliczny. Wyd. 1. Medical Education, Warszawa 2008, s.11-24.
• Alberti KG, Zimmet P, Shaw J: The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
• Kahn R, Buse J, Ferrannini E: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48: 1684-99.[Crossref]
• Gale EA: The myth of the metabolic syndrome. Diabetologia 2005; 48: 1679-83.[PubMed][Crossref]
• Reaven GM: The Metabolic Syndrome: Requiescat in Pace. Clin Chem 2005; 51: 931-38.[PubMed][Crossref]
• Tatoń J, Bernas M: Zespół metaboliczny - kontrowersje wokół akademickiej debaty i realiów praktyki chirurgicznej. Endokrynologia, Otyłość i Zaburzenia Przemiany Materii 2008; 5: 13-26.
• Border WA, Noble N: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-92.
• Taylor PD, Poston L: The effect of hyperglycemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 1994; 113: 801-08.
• Sobel BE, Woodcock-Mitchell J, Schneider DJ et al.: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-21.[Crossref]
• Sterin-Borda L, Franchi AM, Borda ES et al.: Augmented thromboxane generation by mesenteric arteries from pancreatectomized diabetic dogs is coincident with the vascular tone enhancement evoked by Na arachidonate and prostacyclin. Eur J Pharmacol 1984; 103: 211-21
• Jandeleit-Dahm K, Allen TJ, Youssef S et al.: Is there a role for endothelin antagonists in diabetic renal disease? Diabetes Obes Metab 2000; 2: 15-24.[Crossref]
• Staessen JA, Thijs L, O'Brien ET et al.: Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens 2002; 15: 835-43.[Crossref]
• King GL, Goodman AD, Buzney S et al.: Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985; 75: 1028-36.
• Hausberg M, Hoffman RP, Somers VK et al.: Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension 1997; 293: 700-05.
• O'Keefe JH, Lurk JT, Kahatapitiya RC et al.: The renin-angiotensin-aldosterone system as a target in coronary disease. Curr Atheroscler Rep 2003; 5: 124-30
• Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.[Crossref]
• Nisoli E, Briscini L, Giordano A et al.: Tumor necrosis factor alpha mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. Proc Natl Acad Sci USA 2000; 97: 8033-38.[Crossref]
• Pupek-Musialik D, Bogdański P, Łuczak M et al.: Tumor necrosis factor - α - the missing link between obesity and insulin resistace? Atherosclerosis: Risk factors, diagnosis and treatment. Monduzzi Editore 2002; 441-44.
• Poirier P, Eckel RH: Obesity and cardiovascular disease. Curr Atheroscler Rep 2002; 4: 448-53.[PubMed][Crossref]
• Aucott L, Poobalan A, Smith WC et al.: Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005; 45: 1035-41.[Crossref]
• Sjöström CD, Peltonen M, Wedel H et al.: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 20-25.[PubMed][Crossref]
• Fox CS, Massaro JM, Hoffmann U et al.: Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.[Crossref][PubMed]
• Oda A, Taniguchi T, Yokoyama M. et al.: Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001; 47: 141-50.[PubMed]
• Bodary PF, Westrick RJ, Wickenheiser KJ et al.: Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287: 1706-09.
• Miczke A, Bryl W, Bogdański P i wsp.: Ocena stężenia adiponektyny u pacjentów z ostrym zespołem wieńcowym. Nadciśnienie Tętnicze 2005; 9: 31-06.
• Bogdański P, Musialik K, Szulińska M et al.: Ocena stężenia rezystyny u pacjentów z nadciśnieniem tętniczym i zespołem metabolicznym. Endokrynologia, Otyłość i Zaburzenia Przemiany Materii 2006; 4: 116-21.
• Hall JE.: Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997; 10: 49S-55S[Crossref]
• Gorter PM, Olijhoek JK, van der Graaf Y et al.: Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004; 173: 363-69.
• Noszczyk W, Andziak P: Przewlekłe niedokrwienie kończyn dolnych. W: Chirurgia Tętnic i żył obwodowych pod red. Noszczyk W. Warszawa 2007: 563-95.
• Olijhoek JK, van der Graaf Y, Banga JD et al.: The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004; 25: 342-48.[Crossref]
• Andziak P: Chirurgia pozaczaszkowych tętnic mózgowych. PZWL, Warszawa 2007.
• Bots ML, Hofman A, De Jong PT et al.: Common carotid intima-media thickness as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam Study. Ann Epidemiol 1996; 6: 147-53.[Crossref]
• O'Leary DH, Polak JF, Kronmal RA et al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
• Lowe GD: Common risk factors for both arterial and venous thrombosis. Br J Haematol 2008; 140: 488-95.
• Agnelli G, Becattini C: Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006; 4: 1886-90.[Crossref][PubMed]
• Ay C, Tengler T, Vormittag R et al.: Venous thromboembolism - a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374-80.[Crossref][PubMed]
• Palomo I, Alarcón M, Moore-Carrasco R et al.: Hemostasis alterations in metabolic syndrome (review). Int J Mol Med 2006; 18: 969-74.
• Ageno W, Becattini C, Brighton T et al.: Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.[PubMed][Crossref]
• Prandoni P, Bilora F, Marchiori A et al.: An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41.
• Becattini C, Agnelli G, Prandoni P et al.: A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26: 77-83.
• Després JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-87.
• Weiss CA, Lakshman TV, Schwartz RW: Current diagnosis and treatment of cholecystitis. Curr Surg 2002; 59: 51-54.[PubMed][Crossref]
• McMahon AJ, Baxter JN, O'Dwyer P: Pathogenesis and treatment of gallstones. N Engl J Med 1993; 328: 1854-55.
• Degowska M, Bednarczuk A, Rydzewska G: Ostre zapalenie trzustki, obraz kliniczny, leczenie - standardy i nowości. Nowa Klinika 2004; 11-12.
• Yadav D, Pitchumoni CS: Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003; 36: 54-62.[PubMed][Crossref]
• Abu Hilal M, Armstrong T: The impact of obesity on the course and outcome of acute pancreatitis. Obes Surg 2008; 18: 326-28.[PubMed][Crossref]
• Hölscher AH, Bollschweiler E, Gutschow C: GERD and complications: when is surgery necessary? Z Gastroenterol 2007; 45: 1150-55.[PubMed][Crossref]
• Hampel H, Abraham NS, El-Serag HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211.
• Sifrim D: Relevance of volume and proximal extent of reflux in gastro-oesophageal reflux disease. Gut 2005; 54: 175-78.[PubMed][Crossref]
• Kuriyama S, Tsubono Y, Hozawa A et al.: Obesity and risk of cancer in Japan. Int J Cancer 2005; 113: 148-57.
• Samanic C, Gridley G, Chow WH et al.: Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004; 15: 35-43.[Crossref]
• Suba Z, Ujpál M: Correlations of insulin resistance and neoplasms. Magy Onkol 2006; 50: 127-35.[PubMed]
• Czyżyk A, Szczepanik Z: Diabetes mellitus and cancer. Eur J Intern Med 2000; 11: 245-252.[PubMed][Crossref]
• Strickler HD, Wylie-Rosett J, Rohan T et al.: The relation of type 2 diabetes and cancer. Diabetes Technol Ther 2001; 3: 263-74.[PubMed]
• Silverman DT, Schiffman M, Everhart J et al.: Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830-37.[Crossref]
• Hu FB, Manson JE, Liu S et al.: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91: 542-47.
• Bruning PF, Bonfrèr JM, van Noord PA et al.: Insulin resistance and breast-cancer risk. Int J Cancer 1992; 52: 511-16.[Crossref]
• Freeman HJ: Risk of gastrointestinal malignancies and mechanisms of cancer development with obesity and its treatment. Best Pract Res Clin Gastroenterol 2004; 18: 1167-75.[PubMed]
• Rubenstein JH, Davis J, Marrero JA et al.: Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther 2005; 22: 267-71.[PubMed][Crossref]
• Frczek M, Krawczyk M: Operacyjne leczenie otyłości. W: Szmidt (red) Podstawy chirurgii. Wyd. 1. Medycyna Praktyczna, Kraków 2004; s. 708-14.
• Wyleżoł M: Zespół metaboliczny. Otyłość celem chirurga bariatry - kiedy rozważać? W: Mamcarz A (red) Zespół metaboliczny. Wyd. 1. Medical Education, Warszawa 2008; s.555-65.
• Mason EE: Vertical banded gastroplasty for obesity. Arch Surg 1982; 117: 701-06.[PubMed][Crossref]
• Wyleżoł M, Pardela M, Gluck M et al.: Swedish adjustable gastric band (SAGB) implanted laparoscopically in the treatment of morbid obesity-the first experience in Poland. Med Sci Monit 2000; 6: 441-45.
• Mason EE, Printen KJ, Hartford CE et al.: Optimizing results of gastric by-pass. Ann Surg 1975; 182: 405-14.
• Scopinaro N, Gianetta E, Civalleri D et al.: Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg 1979; 66: 618-20.[Crossref][PubMed]
• Buchwald H, Estok R, Fahrbach K et al.: Trends in mortality in bariatric surgery: a systematic review and metaanalysis. Surgery 2007; 142: 621-32.
• Sauerland S, Angrisani L, Belachew M et al.: Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc 2005; 19: 200-21.[Crossref]
• Sjöström L, Narbro K, Sjöström CD et al.: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-52.
• Christou NV, Sampalis JS, Liberman M et al.: Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416-23.
• Adams TD, Gress RE, Smith SC et al.: Longterm mortality after gastric by-pass surgery. N Engl J Med 2007; 357: 753-61.
• Buchwald H, Moore RB, Varco RL: Ten years clinical experience with partial ileal by-pass in management of the hyperlipidemias. Ann Surg 1974; 180: 384-92.
• Buchwald H, Williams SE, Matts JP et al.: Overall mortality in the program on the surgical control of the hyperlipidemias. J Am Coll Surg 2002; 195: 327-31.
• Pories WJ, MacDonald KG, Flickinger EG et al.: Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215: 633-42.
• Angrisani L, Favretti F, Furbetta F et al.: Italian Group for Lap-Band System: results of multicenter study on patients with BMI < or =35 kg/m2. Obes Surg 2004; 14: 415-18.
• Dixon JB, O'Brien PE, Playfair J et al.: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316-23.
• Cohen R, Pinheiro JS, Correa JL et al.: Laparoscopic Roux-en-Y gastric by-pass for BMI < 35 kg/m2: a tailored approach. Surg Obes Relat Dis 2006; 2: 401-04.
• Dziurowicz-Kozłowska A, Lisik W, Wierzbicki Z et al.: Health-related quality of life after the surgical treatment of obesity. J Physiol Pharmacol 2005; 56: 127-34.

Identifiers

DOI

10.2478/v10035-009-0071-4